Literature DB >> 21056950

Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: case report and a review of the literature.

Jurjen S Lagas1, Jiri F P Wagenaar, Alwin D R Huitema, Michel J X Hillebrand, Cornelis H W Koks, Victor E A Gerdes, Desiderius P M Brandjes, Jos H Beijnen.   

Abstract

Morphine-6-glucuronide, the active metabolite of morphine, and to a lesser extent morphine itself are known to accumulate in patients with renal failure. A number of cases on non-lethal morphine toxicity in patients with renal impairment report high plasma concentrations of morphine-6-glucuronide, suggesting that this metabolite achieves sufficiently high brain concentrations to cause long-lasting respiratory depression, despite its poor central nervous system penetration. We report a lethal morphine intoxication in a 61-year-old man with sickle cell disease and renal impairment, and we measured concentrations of morphine and morphine-6-glucuronide in blood, brain and cerebrospinal fluid. There were no measurable concentrations of morphine-6-glucuronide in cerebrospinal fluid or brain tissue, despite high blood concentrations. In contrast, the relatively high morphine concentration in the brain suggests that morphine itself was responsible for the cardiorespiratory arrest in this patient. Given the fatal outcome, we recommend to avoid repeated or continuous morphine administration in renal failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056950     DOI: 10.1177/0960327110388962

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  3 in total

1.  Associations of Opioid Prescriptions with Death and Hospitalization across the Spectrum of Estimated GFR.

Authors:  Tessa K Novick; Aditya Surapaneni; Jung-Im Shin; G Caleb Alexander; Lesley A Inker; Eric A Wright; Alex R Chang; Morgan E Grams
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-03       Impact factor: 8.237

2.  Opioid Use in Adults With Sickle Cell Disease Hospitalized During Vaso-Occlusive Crisis: A Systematic Review.

Authors:  Jennel C Osborne; Zainab Osakwe; Michelle Odlum
Journal:  J Hematol       Date:  2021-04-27

3.  Patient considerations in the use of tapentadol for moderate to severe pain.

Authors:  Nalini Vadivelu; Yili Huang; Brian Mirante; Michael Jacoby; Ferne R Braveman; Roberta L Hines; Raymond Sinatra
Journal:  Drug Healthc Patient Saf       Date:  2013-07-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.